Submitted FDA De Novo application for ARC-EX(®) System

                 Successfully raised EUR 20M in equity capital
         Announced positive top-line results from Up-LIFT pivotal study

Forged partnership to provide rapid access to US Veterans Health Administration
Continued to pioneer brain-computer interface therapies for SCI
EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical
N.V. (Euronext: ONWD), a medical technology company creating innovative spinal
cord stimulation therapies to restore movement, function, and independence in
people with spinal cord injury (SCI), today announces its Full Year 2023
Financial and Operating Results.
"In 2023, we made substantial progress against our objectives and laid the
foundation to bring our ARC-EX System to the US market later this year," said
Dave Marver, CEO of ONWARD Medical. "We are off to a strong start again in
2024, raising EUR 20M in equity capital and submitting our De Novo application
to the FDA for the ARC-EX System."
Full Year 2023 and Early 2024 Highlights
Clinical and Development:

  * In April 2023 at the American Academy of Neurology Annual Meeting,
    neurosurgeon Dr. James Guest of the University of Miami and the Miami
    Project to Cure Paralysis shared that in addition to meeting all primary
    safety and effectiveness endpoints, the Up-LIFT pivotal study demonstrated
    that 72% of participants responded to ARC-EX Therapy(1).
  * In May 2023, Nature published on the progress of a participant from a 2021
    clinical feasibility study in which the Company's ARC-IM(®) Therapy was
    paired with an implanted brain-computer interface (BCI) for the first time,
    resulting in that individual gaining augmented control over when and how he
    moved his paralyzed legs. In August 2023, the Company also completed the
    successful first-in-human use of an implanted BCI paired with the ARC-IM

System to help a person with SCI recover thought-driven movement in his arms

    and hands. The Company calls this combined platform that enables thought-
    driven movement the "ARC-BCI(TM) System."

* Also in May 2023, the Company completed the successful first-in-human use of the ARC-IM Lead, designed to deliver ARC Therapy to areas of the spinal cord

    responsible for a specific function, such as mobility or blood pressure
    regulation. The Company is developing a portfolio of ARC-IM Leads, each
    optimized for placement on a different area of the spinal cord.

* In September 2023, the Company expanded its HemON clinical feasibility study to explore use of the ARC-IM System to improve blood pressure regulation
after SCI with the addition of Sint Maartenskliniek in the Netherlands. This

    additional research site prepares the Company for expected Q4 2024
    initiation of a global pivotal trial called Empower BP to assess the safety
    and efficacy of ARC-IM Therapy to improve blood pressure regulation.
  * In November 2023, the Company announced a publication in Nature Medicine
    (https://www.nature.com/articles/s41591-023-02584-1) highlighting the
    potential for ARC-IM Therapy to address gait challenges related to
    Parkinson's disease. Also in November, ONWARD Medical research partner
    .NeuroRestore was awarded a $1 million grant from The Michael J. Fox
    Foundation for Parkinson's Research (MJFF) to implant the Company's ARC-IM
    System and investigate the impact of ARC-IM Therapy in six additional
    participants with Parkinson's disease.
  * In 2023, the Company was awarded five new Breakthrough Device Designations
    (BDDs) by the US Food & Drug Administration (FDA) for its ARC Therapy
    platforms, bringing the Company's total number of BDDs to 9. A 10th BDD was
    added for ARC-BCI in February 2024.
  * In March 2024, ONWARD was only the second BCI company admitted into the
    FDA's new Total Product Lifecycle Advisory Program (TAP) for its brain-
    computer interface technology.
  * In April 2024, the Company announced it had submitted a De Novo application
    to the US FDA to obtain regulatory clearance to begin marketing its non-
    invasive ARC-EX System in the United States. Clearance is expected Q4 2024.

Intellectual Property:

  * The Company was issued more than 50 new patents during 2023, bringing its
    total number of issued patents to more than 240, further strengthening its
    first-mover advantage.

Commercial:
* In September, the Company announced a partnership with Lovell Government
Services (Lovell), a Service-Disabled Veteran-Owned Small Business (SDVOSB).

    Lovell is a government vendor and third-party logistics provider partnering
    with more than one hundred US healthcare providers. The two-year
    distribution agreement gives the Company contract access to the United

States Veterans Health Administration, the world's largest healthcare system providing SCI care, and the US Department of Defense Military Health System, the world's largest military healthcare provider.
Corporate:

  * In Q1, the Company strengthened its leadership team, appointing Erika Ross
    Ellison as Vice President, Global Clinical, Regulatory, and Quality, and
    Sarah Moore as Vice President, Global Marketing.
  * In Q2, Bryan, Garnier & Co reinitiated research coverage of ONWARD Medical
    following the appointment of a new equity research analyst. In 2024, KBC
    Securities and Stifel both initiated research coverage of the Company.

Equity research analysts from 5 investment banks now cover ONWARD, each with

    a Buy rating and target price at a substantial premium to the current share
    price.
  * In Q3, Robert Odell joined the Company as Vice President of Operations.
    Robert was formerly President and Chief Operating Officer of Cardiac
    Insight, Inc. Prior to that, he served as COO of Cardiac Science
    Corporation, a publicly traded manufacturer of Class II and Class III
    medical devices.

Financial:

  * The Company ended the year with net cash of EUR 29.8M (2022: EUR 61.8M).
  * Management confirmed that with the gross proceeds of EUR 20.0M from the
    share capital increase in March 2024, the Company has a cash runway through
    mid-2025.
  * For 2023, the Company reported an operating loss of EUR 35.5M compared to
    EUR 32.0M in 2022.

+-----------------------------------------------+--------------+--------------+

| In EUR millions                               |              |              |
| For the twelve-month period ended December 31 |     2023     |     2022     |

+-----------------------------------------------+--------------+--------------+
| Total Revenues & Other Income | 0.5 | 2.1 |
+-----------------------------------------------+--------------+--------------+
| Total Operating Expenses | (36.0 ) | (34.2 ) |
+-----------------------------------------------+--------------+--------------+
| Operating Loss for the Period | (35.5 ) | (32.0 ) |
+-----------------------------------------------+--------------+--------------+
| Net Finance Expenses | (0.6 ) | (1.5 ) |
+-----------------------------------------------+--------------+--------------+
| Income Tax Expenses | (0.1 ) | 0.8 |
+-----------------------------------------------+--------------+--------------+
| Net Loss for the Period | (36.2 ) | (32.8 ) |
+-----------------------------------------------+--------------+--------------+
| | | |
+-----------------------------------------------+--------------+--------------+
| At | 31 Dec. 2023 | 31 Dec. 2022 |
+-----------------------------------------------+--------------+--------------+
| Cash position at the end of the period | 29.8 | 61.8 |
+-----------------------------------------------+--------------+--------------+
| Interest Bearing Loans | (15.3 ) | (12.7 ) |
+-----------------------------------------------+--------------+--------------+
| Equity | 17.9 | 52.6 |
+-----------------------------------------------+--------------+--------------+
Total Revenues & Other Income

  * Other Income, mainly grant income, decreased to EUR 0.5M (2022: EUR 2.1M)
    mainly due to a change in recognition of grant income.

Total Operating Expenses
* Total Operating expenses increased during 2023 by EUR 1.8M to EUR 36.0M
(2022: EUR 34.2M). Research & Development (including Clinical) expenses were stable at EUR 18.8M (2022: EUR 18.9M), mainly including costs to finalize
all components of the ARC-EX platform for FDA submission. Marketing expenses

    increased from EUR 2.0M in 2022 to EUR 2.9M driven by heightened market
    access activities in preparation for ARC-EX launch, including pricing
    studies and congress attendance to build awareness for the Company's
    therapies within the SCI Community. General and Administrative expenses
    increased by 7% up to EUR 11.3M in 2023 (2022: EUR 10.6M) mainly due to the
    strengthening of overall operational capabilities to prepare the launch of
    the Company's first commercial product.

Net Finance Expenses
* Net Finance expense decreased from EUR 1.5M in 2022 to EUR 0.6M in 2023 due
to higher financial income related to interest earned from our positive cash

    balance in fixed term deposits. The financial expense is related to the
    interest expense on the Company's longstanding innovation loan from the
    Netherland Enterprise Agency (RVO).

Net Loss for the Period

  * The Company realized a Net Loss for the period of EUR 36.2M versus EUR
    32.8M in 2022 driven by the lower grant income and higher operating
    expenses.

Net Cash Position
* The Company ended the year 2023 with a net cash position of EUR 29.8M (2022: EUR 61.8M). Cash outflow from operating activities increased from EUR 26.7M
in 2022 to EUR 32.3M in 2023 driven by the higher operating loss and changes

    in working capital. Cash flow from financing activities was EUR 0.8M
    positive (2022: EUR 0.6M negative) driven by proceeds from the RVO loan.

2024 Outlook
Innovation, Clinical and Regulatory Developments:
* On April 2(nd), the Company announced it submitted a De Novo application for FDA clearance for the ARC-EX System, with an anticipated authorization to
commercialize the platform in the US in the second half of 2024. The Company aims to apply for CE Mark and European authorization in 2025.
* Based on positive feedback from potential customers on the value of the ARC- EX System, now demonstrated to be the first-ever therapy to restore hand and

    arm function after chronic SCI, the Company anticipates an approximate list
    price of USD 30,000. In addition, the Company expects to supplement revenue
    by offering tiered service packages.
  * The Company plans to apply for FDA IDE approval and to begin its global
    pivotal trial for the ARC-IM System, called Empower BP, in the second half
    of 2024 to provide the evidence necessary to ultimately submit a pre-market
    approval (PMA) application to the US Food and Drug Administration (FDA) and
    other global regulatory bodies.

* The Company intends to gain additional clinical data and experience with its

    implantable ARC-IM System in 2024, with several implants planned with
    support from the Michael J. Fox Foundation for Parkinson's Research and
    several ARC-IM System implants planned in combination with an implanted
    brain-computer interface (BCI) with support from the European Innovation
    Council. The Company calls this BCI-augmented system, ARC-BCI.

Corporate:

  * At year-end 2023, the Company anticipated its cash position would fuel
    operations through the end of 2024. In March 2024, the Company completed a
    EUR 20M equity financing that strengthened its cash position to support
    investments in product development, clinical trials, operational and
    commercial capabilities, and extending its cash runway through mid-2025.

To learn more about ONWARD Medical's commitment to partnering with the SCI Community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.
*All ONWARD Medical devices and therapies, including but not limited to ARC-
IM(®), ARC-EX(®), ARC-BCI((TM)), and ARC Therapy((TM)), alone or in combination with a
brain-computer interface (BCI), are investigational and not available for
commercial use.
About ONWARD Medical
ONWARD(®) Medical is a medical technology company creating therapies to restore
movement, function, and independence in people with spinal cord injury (SCI) and
movement disabilities. Building on more than a decade of scientific discovery,
preclinical, and clinical research conducted at leading hospitals,
rehabilitation clinics, and neuroscience laboratories, the Company has developed
ARC Therapy((TM)), which has been awarded ten Breakthrough Device Designations from
the US Food and Drug Administration (FDA).
ONWARD ARC Therapy, which can be delivered by external ARC-EX(®) or implantable
ARC-IM(®) systems, is designed to deliver targeted, programmed spinal cord
stimulation. Positive results were presented in 2023 from the Company's pivotal
study, called Up-LIFT, evaluating the ability for transcutaneous ARC Therapy to
improve upper extremity strength and function. The Company has submitted its
regulatory application to the FDA for clearance of the ARC-EX System in the US
and is preparing for regulatory submission in Europe. In parallel, the Company
is conducting studies with its implantable ARC-IM Therapy, which demonstrated
positive interim clinical outcomes for improved blood pressure regulation
following SCI. Other ongoing studies include use of ARC-IM Therapy to address
mobility after SCI and gait challenges in Parkinson's disease as well as using
the ARC-BCI platform to restore thought-driven movement of both upper and lower
limbs after SCI.
Headquartered in Eindhoven, the Netherlands, ONWARD Medical has a Science and
Engineering Center in Lausanne, Switzerland and a US office in Boston,
Massachusetts. The Company is listed on Euronext Brussels and Amsterdam (ticker:
ONWD).
For more information, visit ONWD.com, and connect with us on LinkedIn and
YouTube.
For Media Inquiries:
Aditi Roy, VP Communications
media@onwd.com (mailto:media@onwd.com)
For Investor Inquiries:
Khaled Bahi, Interim CFO
investors@onwd.com (mailto:investors@onwd.com)
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-
looking, which reflect the Company's or, as appropriate, the Company directors'
current expectations and projections about future events. By their nature,
forward-looking statements involve several risks, uncertainties, and assumptions
that could cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. These risks,
uncertainties, and assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of factors
including, but not limited to, changes in demand, competition, and technology,
can cause actual events, performance, or results to differ significantly from
any anticipated development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the future. As a
result, the Company expressly disclaims any obligation or undertaking to release
any update or revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events, conditions,
assumptions, or circumstances on which these forward-looking statements are
based. Neither the Company nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are free from
errors nor does either accept any responsibility for the future accuracy of the
forward-looking statements contained in this press release or the actual
occurrence of the forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the date of this press
release. All ONWARD Medical devices and therapies referenced here, including but
not limited to ARC-IM(®), ARC-EX(®), ARC-BCI((TM)) and ARC Therapy((TM)), are
investigational and not available for commercial use.
(_______________________________________
1) Responder defined as a participant who met or exceeded the minimally
important difference (MID) criteria for at least one outcome of the strength
domain and at least one outcome of the functional performance domain. Responders
had an average time since injury of 6 years, with a range of 1-34 years.
Â